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Background: Radiolabelled bombesin (BN) conjugates are promising radiotracers for imaging and therapy of breast
and prostate tumours, in which BN2/gastrin-releasing peptide receptors are overexpressed. We describe the
influence of the specific activity of a 177Lu-DOTA-PEG5k-Lys-B analogue on its therapeutic efficacy and compare it
with its non-PEGylated counterpart.
Methods: Derivatisation of a stabilised DOTA-BN(7–14)[Cha13,Nle14] analogue with a linear PEG molecule of 5 kDa
(PEG5k) was performed by PEGylation of the E-amino group of a β3hLys-βAla-βAla spacer between the BN sequence
and the DOTA chelator. The non-PEGylated and the PEGylated analogues were radiolabelled with 177Lu. In vitro
evaluation was performed in human prostate carcinoma PC-3 cells, and in vivo studies were carried out in nude
mice bearing PC-3 tumour xenografts. Different specific activities of the PEGylated BN analogue and various dose
regimens were evaluated concerning their therapeutic efficacy.
Results: The specificity and the binding affinity of the BN analogue for BN2/GRP receptors were only slightly
reduced by PEGylation. In vitro binding kinetics of the PEGylated analogue was slower since steady-state condition
was reached after 4 h. PEGylation improved the stability of BN conjugate in vitro in human plasma by a factor of
5.6. The non-PEGylated BN analogue showed favourable pharmacokinetics already, i.e. fast blood clearance and
renal excretion, but PEGylation improved the in vivo behaviour further. One hour after injection, the tumour uptake
of the PEG5k-BN derivative was higher compared with that of the non-PEGylated analogue (3.43 ± 0.63% vs.
1.88 ± 0.4% ID/g). Moreover, the increased tumour retention resulted in a twofold higher tumour accumulation at
24 h p.i., and increased tumour-to-non-target ratios (tumour-to-kidney, 0.6 vs. 0.4; tumour-to-liver, 8.8 vs. 5.9, 24 h p.i.).
In the therapy study, both 177Lu-labelled BN analogues significantly inhibited tumour growth. The therapeutic efficacy
was highest for the PEGylated derivative of high specific activity administered in two fractions (2 × 20 MBq= 40 MBq) at
day 0 and day 7 (73% tumour growth inhibition, 3 weeks after therapy).
Conclusions: PEGylation and increasing the specific activity enhance the pharmacokinetic properties of a
177Lu-labelled BN-based radiopharmaceutical and provide a protocol for targeted radionuclide therapy with a
beneficial anti-tumour effectiveness and a favourable risk-profile at the same time.
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Prostate and breast cancers are the most frequently
diagnosed forms of cancer in the USA. Especially in
addressing metastatic and small-volume diseases, it is
essential to investigate, alongside conventional therapies,
alternative treatments, such as peptide receptor radio-
nuclide therapy (PRRT). The fact that certain tumour
types overexpress, receptors for peptide-hormones
provide the basis for successful use of radiolabelled
peptide analogues as tumour tracers in nuclear medi-
cine. The mammalian gastrin-releasing peptide receptor
(BN2/GRP) [1,2] is particularly overexpressed in several
human tumours, including prostate, breast and small-
cell lung cancers [3-5]. The tetradecapeptide bombesin
(BN) shows high binding affinity for these BN2/GRP
receptors. Using BN conjugates for specific delivery of
radionuclides into the above-mentioned tumours is
therefore a promising strategy for diagnostic and thera-
peutic purposes.
BN analogues, however, present certain problems
regarding therapy. They show poor enzymatic stability
in vivo, which might prevent sufficient localisation at the
target site. Furthermore, high accumulation and reten-
tion in healthy organs, which express the BN2/GRP
receptor, increase the risk of side effects. Moreover,
kidney toxicity, which was observed and investigated in
PRRT with somatostatin analogues in clinical studies
[6-8], may also hold true for BN analogues. Finally,
several side effects were elicited from intravenous (i.v.)
injection of BN agonists in humans. Therefore, a high
specific activity of the radiolabelled BN agonist may be
important in minimising such undesired effects.
Until now, the research has focused on optimising BN
conjugates for nuclear imaging of cancer which overex-
presses BN2/GRP receptors. Different BN analogues were
labelled with diagnostic single-photon emission computed
tomography (SPECT) and positron emission tomography
(PET) radionuclides, such as 111In [9-11], 99mTc [12-15],
18 F [16-18], 68Ga [19,20] and 64Cu [21], and were evalu-
ated in preclinical studies for their ability to detect BN2/
GRP receptor-positive lesions. However, only a few radi-
olabelled BN analogues have been tested in clinics on their
diagnostic potential [20,22]. So far, only three BN analo-
gues, AMBA, DOTA-8-AOC-BN(7–14)NH2 and DOTA-
PESIN, have been rated in preclinical investigations on
their potential for radionuclide therapy [23-25]. They were
radiolabelled with 177Lu (beta-emitter, Eβ−max 0.497 MeV,
half-life of 6.7 days) or with 213Bi (alpha-emitter, Eβ−max
1.423 MeV, Eαmax 5.982 MeV, half-life of 45.6 min). The
in vitro and in vivo evaluations of our 177Lu-DOTA-Lys-
BN analogue (DOTA-β3hLys-βAla-βAla-Gln7-Trp8-Ala9-
Val10-Gly11-His12-Cha13-Nle14-NH2) showed pharmacoki-
netic properties which are comparable to that reported for
the above-mentioned BN analogues. Therefore, we wantedto improve the radiotherapy-relevant characteristics fur-
ther by PEGylating 177Lu-DOTA-Lys-BN.
Our preclinical study with a series of 99mTc(CO)3-
labelled PEGylated BN analogues showed that PEGylation
is an effective strategy to improve the therapy-relevant
characteristics, which include higher tumour uptake,
improved tumour retention and lower uptake into non-
target tissue. The PEG entity of 5 kDa was established as
the optimal PEG size because it improved these features
best [26].
The BN analogues of the current study were therefore
based on one of our stabilised analogues (Gln7-Trp8-
Ala9-Val10-Gly11-His12-Cha13-Nle14-NH2) containing a
β3hLys-βAla-βAla spacer (Figure 1) [14]. The peptide was
equipped with a 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA) chelator to provide the analogue
DOTA-β3hLys-βAla-βAla-Gln7-Trp8-Ala9-Val10-Gly11-
His12-Cha13-Nle14-NH2 (referred to as DOTA-Lys-BN,
Figure 1a). We hypothesised that PEGylating this DOTA-
Lys-BN would lead to the same favourable characteristics
seen with PEGylated 99mTc-based BN analogues. Derivati-
sation of the DOTA-Lys-BN analogue with a linear PEG
molecule of 5 kDa (PEG5k) was performed by PEGylation
of the E-amino group of the lysine residue. The resulting
PEGylated BN (referred to as DOTA-PEG5k-Lys-BN,
Figure 1b) as well as the DOTA-Lys-BN were then
radiolabelled with 177Lu. We chose this radionuclide
because it is currently used together with 90Y for PRRT
with somatostatin analogues on a routine basis in clinics
[27,28] and because it proved to be less problematic
concerning kidney toxicity in comparison with the
90Y-radiolabelled somatostatin analogue [8,27]. Fur-
thermore, application of 177Lu allows imaging and
PRRT at the same time owing to γ-ray emissions of
suitable energy for SPECT, which enables dosimetry
calculations and therapy monitoring [29].
In the current study, the new 177Lu-labelled DOTA-
Lys-BN and DOTA-PEG5k-Lys-BN analogues were
tested in vitro in human prostate carcinoma PC-3 cells
and in PC-3 tumour bearing mice. They were compared
in order to evaluate the effect of PEGylation on in vivo
pharmacokinetics and their therapeutic effectiveness.
Apart from looking at the anti-tumour efficacy, we also
investigated the optimal risk-benefit profile by varying
the specific activity of the radiolabelled DOTA-PEG5k-
Lys-BN analogue and assessed the efficacy of PRRT by
varying the number and the interval of the 177Lu-
DOTA-PEG5k-BN doses. For an estimation of potential
kidney toxicity, the renal function was monitored with
quantitative 99mTc-DMSA scintigraphy.
Methods
Sources of materials, equipment, peptide synthesis and
PEGylation are presented in Additional file 1.
Figure 1 Chemical structures of (a) DOTA-Lys-BN and (b) DOTA-PEG5k-Lys-BN analogues.
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All data are presented as mean ± SD. The in vivo data
were statistically analysed with a t test (Microsoft Excel
software). All analyses were 2-tailed and considered as
type 3 (two-sample unequal variance); P< 0.05 was con-
sidered statistically significant.177Lu labelling of the DOTA-lys-BN and DOTA-PEG5k-lys-
BN analogues
For high specific activity labelling, 16 μl of approxi-
mately 400 MBq 177LuCl3 (714.3 GBq/μmol) were added
to a mixture of 20 μl ammonium acetate solution
(0.5 M, pH 7.5), 84 μl HCl (0.04 M), 5 μl ascorbic acid
solution (0.05 M) and 5.6 nmol of BN analogue (high
specific, 66 MBq/nmol peptide). The final solution (pH
4.5) was heated at 75 °C for 15 min (Additional file 1:
Figure S7). For the 177Lu-labelled BN analogues of low
specific activity (6.6 MBq/nmol peptide), unlabelled BN
analogue was added to the high specific labelling solu-
tion to reach the respective concentration.Metabolic stability in human plasma
The labelled analogues were incubated with human
plasma (final concentration, 10 MBq/0.6 ml) at 37 °C for
various time intervals up to 12 days. After incubation,
proteins were precipitated with acetonitrile/ethanol (1:1)
and TFA (0.1%) and then centrifuged. The supernatant
was analysed with RP-high-performance liquid chroma-
tography (HPLC) equipped with a radioactivity detector.
The radioactivity chromatograms showed different peaks
which corresponded to the intact peptide and the differ-
ent degradation products. The experiments were per-
formed two times.Internalisation and externalisation studies
For internalisation, PC-3 cells at confluence were placed
in six-well plates and left to attach overnight. Cells were
incubated with the labelled analogues (4 kBq) in culture
medium for 0.5, 1, 2, 4 and 24 h at 37 °C. Non-specific
binding was determined with 1 μM unlabelled BN
(1–14). After the different incubation times, cells
were twice washed with cold phosphate buffered saline
(PBS) to discard unbound peptide. Surface-bound activity
was removed by two 5-min acid washes (50 mM glycin-
HCl, 100 mM NaCl, pH 2.8). Afterwards, the cells were
washed with cold PBS, and lysed with 1 N NaOH twice.
Surface-bound and internalised radioactivities were mea-
sured in the gamma counter.
For externalisation, PC-3 cells were incubated with the
labelled analogues (60 kBq) in culture medium at 37 °C
for 1 h. After incubation, the supernatant was discarded,
and the cells were twice washed with cold PBS. The cells
were then incubated again at 37 °C in culture medium
for 0.5, 1, 2.5, 5 and 24 h. At each time point, the super-
natant was collected, the cells twice washed with cold
PBS and lysed with 1 N NaOH. The supernatant
(released radioactivity) and the cells (bound/internalised
radioactivity) were measured in the gamma counter. All
experiments were carried out two to three times in
triplicate.Biodistribution studies
All animal experiments were conducted in compliance
with the Swiss animal protection laws and with the
ethical principles and guidelines for scientific animal
experimentation established by the Swiss Academy of
Natural Sciences. Biodistribution studies were performed
with 6- to 8-week-old female CD-1 nu/nu mice (20 to
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Germany). For the induction of tumour xenografts, each
mouse received subcutaneously 8 × 106 PC-3 cells in
150 μl culture medium without supplements. The
tumours were allowed to grow for at least 3 weeks. On
the day of the experiment, the mice (3 to 6 per group)
received the radioactive conjugates intravenously. For
the biodistribution studies, the mice were injected with
different specific activities of the radiolabelled BN
analogues (low specific, 6.6 MBq/nmol peptide; high
specific, 66 MBq/nmol peptide). Receptor-blocking
studies were performed using 100 μg of unlabelled BN
(1–14) co-injected with the corresponding radiolabelled
BN analogue. At 1, 4 and 24 h post injection (p.i.), the
animals were euthanised and dissected. Blood, tumours
and various healthy tissues and organs were collected,
weighed and examined for radioactivity. Results are
expressed as percentage of injected dose per gram of
tissue (% ID/g).Dose calculation
The absorbed doses to PC-3 tumours and critical organs
were calculated from the biodistribution studies
(1 MBq/0.1 ml; 0.3 or 3.0 nmol peptide; n= 3 per group).
Under the assumption of rapid accumulation (uptake at
0 h p.i. corresponds to the uptake at 1 h p.i.), the
cumulative radioactivity in each tissue was calculated
(MBq/h) taking biologic elimination and physical decay
into account up to 24 h p.i. and afterwards only physical
decay up to 400 h p.i. The absorbed tumour doses of the
mouse experiments were extrapolated from the sphere
model doses which were calculated by using the software
OLINDA (OLINDA/EXM1.0, Vanderbilt University,
Nashville, TN, USA). The S values for all other tissues of
mice were taken from E Larsson [30]. The absorbed dose
(milligray per mega-Bequerel) was calculated by multi-
plying the area under the curve (AUC) (h; normalised to
1 MBq ID) with the S value (mGy/(MBq?s)). The dose
(in Gy) was calculated by multiplying the absorbed dose
(mGy/MBq) with the amount of radioactivity injected
(20 MBq). The AUC-estimate for an adult male was
obtained by multiplying the AUC of the mice (MBq/h)
with a factor consisting of (total body weightmouse/total
body weightadult male) × organ weightadult male. The sub-
sequent dose calculation was performed using the adult
male model of the software OLINDA.Therapy studies
Therapy studies were conducted in mice bearing PC-3
xenografts. The tumour was assumed to be an ellips-
oid, and its volume was calculated with the formula
Vt ¼ π=6ð ÞLW 2 where L represents the longest dimen-
sion and W the shortest dimension of the tumour.Two weeks post PC-3 inoculation, i.e. the day of the
first injection (day 0), the tumours had an average
volume of 85 mm3. The animals were divided into six
groups of six mice (Table 1). The control group
received an i.v. injection of PBS only (group A).
Another group was injected with unlabelled DOTA-
PEG5k-Lys-BN at a peptide amount of 3.0 nmol (group
B). The treated mice received two equal doses of
20 MBq i.v. either of 177Lu-DOTA-PEG5k-Lys-BN
(groups C to E) or of 177Lu-DOTA-Lys-BN (group F)
at a peptide amount of 0.3 or 3.0 nmol. The injections
were performed either at days 0 and 14 or at days 0
and 7 (Table 1). Body weight and tumour volume of all
mice were quantified 3 times per week. The relative vol-
ume of tumours Vr was defined as Vr =Vt/V0, where Vt
was the measurement at time t (days after the first in-
jection), and V0 was the measurement at day 0. If a
tumour disappeared, Vt was set to 0. Mice were
removed from the study promptly upon fulfilling one
or both of the following criteria: a tumour volume of
≥ 1.5 cm2 or total body weight loss of ≥ 15%. Upon
euthanasia, tumours were collected and embedded in
TissueTek (Sakura Finetek, USA Inc., Torrance, CA,
USA) and frozen for autoradiography.99mTc-DMSA SPECT/CT imaging studies
Three groups of four mice each (groups G to I, Table 1),
which were not xenografted with PC-3 cells, were
included in the therapy study for 99mTc-DMSA tests. An
untreated control group of mice (group G), a treated
group receiving two doses of the 177Lu-DOTA-PEG5k-
Lys-BN analogue at high specific activity (group H) and
a treated group of mice getting two doses of the 177Lu-
DOTA-PEG5k-Lys-BN analogue with low specific activity
(group I). 99mTc-DMSA scans with SPECT/computed
tomography (CT) were obtained 43, 71 and 111 days
after therapy, 2 h after i.v. injection of about 30 MBq
99mTc-DMSA. SPECT scans were acquired with anaes-
thetised mice during 20 min using 15 projections/min.
The images were obtained on an X-SPECT-system
(Gamma Medica, Inc., Northridge, CA, USA) equipped
with a single head SPECT device and a CT device.
SPECT data were acquired and reconstructed with
LumaGEM (version 5.407, Gamma Medica, Northridge,
CA, USA). CT data were acquired with an X-ray CT-sys-
tem (Gamma Medica) and reconstructed with the soft-
ware CoBRA (version 4.5.1, Falls Church, VA, USA).
SPECT and CT data were combined with the software
IDL Virtual Machine (version 6.0, Exelis Visual Informa-
tion Solutions, Inc., McLean, VA, USA). The images
were generated with Amira (version 4.0). Quantification
of the amount of radioactivity in a volume of interest
over the kidneys was performed with Amira (version 4.0,
Figure 2 Metabolic stability of 177Lu-DOTA-Lys-BN and 177Lu-
DOTA-PEG5k-Lys-BN in human plasma.
Table 1 Therapy protocol: classification of therapy groups and specification of administration of the BN analogues
Therapy groups BN analogues Dose and peptide amount Injection time
Mice with PC-3 tumour xenografts A PBS 2 × 100 μl Days 0 and 14
B DOTA-PEG5k-Lys-BN 2 × 3.0 nmol Days 0 and 14
C 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/3.0 nmol each Days 0 and 14
D 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/0.3 nmol each Days 0 and 14
E 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/0.3 nmol each Days 0 and 7
F 177Lu-DOTA-Lys-BN 2 × 20 MBq/0.3 nmol each Days 0 and 14
Mice without PC-3 tumour xenografts G PBS 2 × 100 μl Days 0 and 14
H 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/0.3 nmol each Days 0 and 14
I 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/3.0 nmol each Days 0 and 14
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The PEGylation of the DOTA-Lys-BN analogue (Additional
file 1: Figure S7) as well as the results of the log D and
IC50 determination are presented in Additional file 1.
PEGylation resulted in a slightly increased hydrophil-
icity of the analogue and in an eightfold higher IC50
value compared with that of the non-PEGylated
analogue (15.96 ± 4.42 nM vs. 2.03 ± 0.42 nM). The
177Lu-DOTA-Lys-BN was rapidly degraded by proteases
in human plasma. After 5 days of incubation, it was al-
most entirely metabolised, and only 13.8 ± 5.7% remained
intact. PEGylation resulted in a marked increase in
protease stability; 51.8± 0.9% of 177Lu-DOTA-PEG5k-Lys-
BN still remained intact after 5 days of incubation and
43.7± 0.5% after 11 days. Moreover, the half-life of 177Lu-
DOTA-Lys-BN in human plasma was 1.2 ± 0.3 days,
whereas the half-life of 177Lu-DOTA-PEG5k-Lys-BN was
6.7 ± 1.4 days (Figure 2).
177Lu-DOTA-Lys-BN internalised rapidly into PC-3
cells and reached its maximum within the first hour of
incubation (approximately 30%/106 cells). The PEGy-
lated analogue showed a significantly lower and slower
internalisation into PC-3 cells. After incubation for 4 h,
the internalised fraction was 3.3 ± 1.2%. Externalisation
studies revealed 63.1 ± 4.0% of the internalised 177Lu-
DOTA-Lys-BN externalised within the first 2.5 h. After
24 h, only 13.5 ± 7.2% of the internalised fraction was
found in the cells. In contrast, the externalisation of the
PEGylated analogue was slower (24.2 ± 1.3% after 24 h).
Biodistribution studies
The effect of PEGylation was tested in vivo in mice with
PC-3 tumour xenografts performed with BN conjugates
at an injected peptide amount of 0.075 nmol (Table 2).
The highest tumour uptake of 177Lu-DOTA-Lys-BN(1.88% ID/g) and 177Lu-DOTA-PEG5k-Lys-BN (3.43%
ID/g) was found 1 h p.i., the latter being significantly
higher. Thus, the enhanced enzymatic stability induced
by PEGylation compensated for the lower receptor affin-
ity of DOTA-PEG5k-Lys-BN. Furthermore, the tumour
washout was slightly slower for the PEGylated analogue.
Thus, 1.04% ID/g was found for the 177Lu-DOTA-
PEG5k-Lys-BN 24 h p.i., whereas only 0.54% ID/g of
177Lu-DOTA-Lys-BN remained in the tumour. At 1 h p.
i., both analogues showed their highest uptake in the
pancreas, which expresses GRP receptors (8.68% ID/g
and 9.62% ID/g for 177Lu-DOTA-Lys-BN and 177Lu-
DOTA-PEG5k-Lys-BN, respectively). The liver uptake
of both 177Lu-DOTA-Lys-BN and 177Lu-DOTA-PEG5k-
Lys-BN was low (0.26% ID/g and 0.57% ID/g at 1 h p.i.,
respectively). Kidney accumulation was higher for the
177Lu-DOTA-PEG5k-Lys-BN in comparison with that of
the non-PEGylated analogue at 1 h p.i. (4.89% ID/g vs.
Table 2 Biodistribution (0.3 MBq/0.075 nmol) of 177Lu-labelled BN analogues in nude mice bearing PC-3 tumour
177Lu-DOTA-Lys-BN 177Lu-DOTA-PEG5k-Lys-BN
177Lu-DOTA-Lys-BN 177Lu-DOTA-PEG5k-Lys-BN
Tissue 1 h p.i. 24 h p.i. 1 h p.i. 24 h p.i. 1 h p.i. blocked 1 h p.i. blocked
Blood 0.24 ± 0.07 0.00 ± 0.00 1.54 ± 0.33* 0.01 ± 0.00*
Heart 0.14 ± 0.06 0.01 ± 0.01 0.49 ± 0.05 0.04 ± 0.01
Lung 0.36 ± 0.08 0.02 ± 0.01 1.10 ± 0.15 0.13 ± 0.02
Spleen 0.42 ± 0.12 0.18 ± 0.04 0.72 ± 0.02 0.19 ± 0.03
Kidneys 2.86 ± 0.63 1.41 ± 0.14 4.89 ± 1.33 1.84 ± 0.52
Pancreas 8.68 ± 1.95 4.27 ± 0.85 9.62 ± 2.39 4.87 ± 1.11 0.49 ± 0.22** 0.98 ± 0.59*
Stomach 0.72 ± 0.19 0.10 ± 0.02 1.12 ± 0.15 0.22 ± 0.07
Small intestine 1.38 ± 0.41 0.16 ± 0.03 1.18 ± 0.22 0.17 ± 0.12
Colon 1.64 ± 0.40 0.36 ± 0.09 2.19 ± 0.91 0.45 ± 0.21 0.36 ± 0.07** 0.66 ± 0.14
Liver 0.26 ± 0.09 0.09 ± 0.02 0.57 ± 0.04 0.16 ± 0.09
Muscle 0.20 ± 0.24 0.01 ± 0.00 0.31 ± 0.06 0.42 ± 0.69
Bone 0.36 ± 0.24 0.02 ± 0.01 0.70 ± 0.06 0.58 ± 0.44
Tumour 1.88 ± 0.47 0.54 ± 0.30 3.43 ± 0.63* 1.04 ± 0.04 0.55 ± 0.03* 1.02 ± 0.34**
*P< 0.05; **P< 0.01. Data in percentage of injected dose per gram of tissue (%ID/g), expressed as mean ± SD at 1 and 24 h p.i. (n= 3 to 4).
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was fast for both analogues (1.84% ID/g vs. 1.41% ID/g
at 24 h p.i., respectively). The conjugation of a PEG5k
entity resulted in a significantly longer blood circula-
tion during 1 h p.i., but both derivatives were com-
pletely cleared from blood within 24 h p.i. (Table 2).
Specificity for GRP receptors could be demonstrated
by a co-administration of non-radioactive BN(1–14).
Thus, only the uptake in the receptor-expressing tissues
such as the pancreas, colon and tumour was markedly
reduced (>70%), whereas the inhibition was slightly less
effective for the PEGylated BN analogue (Table 2).
The tumour-to-non-target ratios were similar for both
derivatives. The initial longer circulation time of 177Lu-
DOTA-PEG5k-Lys-BN, however, resulted in lower
tumour-to-blood ratios at 1 and 4 h p.i. compared with
that of the non-PEGylated compound. 177Lu-DOTA-
PEG5k-Lys-BN showed a twofold increase in the
tumour-to-pancreas ratio at all time points and in
tumour-to-kidney and tumour-to-liver ratios at 24 h p.i.
(Figure 3).
In additional biodistribution studies, two ligand doses
of the 177Lu-DOTA-PEG5k-Lys-BN at a peptide amount
corresponding to the amount that was injected in the
therapy studies (high specific, 0.3 nmol; or low specific,
3.0 nmol peptide injected per mouse) were administered.
This showed that the uptake in the receptor-expressing
tissues such as the pancreas and colon was markedly
reduced by applying a high amount of PEGylated peptide
(3.0 nmol). The tumour uptake was also reduced by 29%
and 42% at 1 h p.i. and 24 h p.i. after injection of a high
amount of peptide (Figure 4, Table 3). In comparison, the
tumour-to-blood, tumour-to-liver, tumour-to-kidney and
tumour-to-muscle ratios were approximately twofoldhigher at all time points if 177Lu-DOTA-PEG5k-Lys-BN
was injected at a low molar amount of peptide (0.3 nmol).
The only ratios which revealed a higher value with a high
amount of peptide (3.0 nmol) were the tumour-to-pan-
creas ratios (Table 3).
Dose calculation
After applying 177Lu-DOTA-PEG5k-Lys-BN at a low
molar amount of peptide (0.3 nmol) in a single dose, the
absorbed doses were calculated to be 0.36 Gy/MBq for
the murine kidney, 0.002 Gy/MBq for the blood,
0.02 Gy/MBq for the pancreas and 0.19 Gy/MBq for the
tumour. After the application of 177Lu-DOTA-PEG5k-
Lys-BN at a high amount of peptide (3.0 nmol), however,
the absorbed doses to the murine kidney, blood, pan-
creas and tumour were calculated to be 0.50, 0.002,
0.006 and 0.11 Gy/MBq, respectively. The estimate for
an adult male resulted in absorbed doses to the kidney,
blood and pancreas of 9.4, 0.4 and 21.3 Gy/GBq
(0.3 nmol) and 12.3, 0.4 and 5.2 Gy/GBq (3.0 nmol),
respectively.
Therapy studies
The therapy study was performed according to the
protocol shown in Table 1. In total, 48 mice were
included and divided into six groups of mice bearing
PC-3 tumours (groups A to F; n= 6) and three additional
groups of mice without tumours (groups G to I; n= 4).
All groups of mice which received the 177Lu-labelled BN
analogues (C to F) clearly showed a reduction of tumour
growth in comparison with groups A and B which
received only PBS or unlabelled BN analogue. The
treatment with the non-PEGylated 177Lu-labelled BN
analogue (0.3 nmol; group F) significantly decreased the
Figure 3 Tumour-to-non-target ratios. (a) Tumour-to-blood, (b) tumour-to-pancreas, (c) tumour-to-kidney and (d) tumour-to-liver ratios.
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A and exhibited an inhibition of 53% 3 weeks after the
first dose (Figures 5 and 6). The tumour growth inhib-
ition was higher (63%) with the 177Lu-DOTA-PEG5k-
Lys-BN analogue of high specific activity (group D).
However, the 177Lu-DOTA-PEG5k-Lys-BN analogue of
low specific activity (group C) exhibited only an inhib-
ition of 36%. The most effective tumour growthFigure 4 Influence of the amount of injected peptide on the
biodistribution of 177Lu-DOTA-PEG5k-Lys-BN.inhibition of 73% (3 weeks after the first dose) was
observed when the second dose of the PEGylated BN
analogue of high specific activity was applied 7 days after
the first dose (group E; Figure 6). Mice of group B did
not show an increased tumour growth with respect to
group A (Figure 5), although BN agonists are known to
have mitogenic characteristics.
99mTc-DMSA SPECT/CT imaging studies
Forty-three days after therapy, the renal 99mTc-DMSA
uptake of the treated animals (group H) receiving the
radiotracer of high specific activity was 76,397 counts/
kidney, whereas the uptake of the treated animals receiv-
ing the radiotracer of low specific activity (group I) was
74,949 counts/kidney. Seventy-one days after therapy,
there was no significant difference in the renal 99mTc-
DMSA uptake between groups G, H and I (51,344,
57,147 and 47,692 counts/kidney, respectively); 111 days
after therapy, there was also no significant difference in
the renal 99mTc-DMSA uptake between these three
groups of mice.
Discussion





evaluated for PRRT [23-25]. These compounds were
Table 3 Biodistribution (1 MBq/0.3 or 3.0 nmol) of 177Lu-
DOTA-PEG5k-Lys-BN analogue in nude mice bearing PC-3
tumours
177Lu-DOTA-PEG5k-Lys-BN
1 h p.i. 24 h p.i.
Tissue 0.3 nmol 3.0 nmol 0.3 nmol 3.0 nmol
Blood 0.51 ± 0.09 0.77 ± 0.11* 0.02 ± 0.00 0.02 ± 0.00
Heart 0.22 ± 0.05 0.31 ± 0.09 0.04 ± 0.01 0.05 ± 0.01
Lung 0.92 ± 0.59 2.03 ± 1.64 0.44 ± 0.32 0.58 ± 0.36
Spleen 0.45 ± 0.11 0.39 ± 0.05 0.40 ± 0.06 0.21 ± 0.04
Kidneys 3.11 ± 0.42 3.92 ± 0.59 1.59 ± 0.42 2.12 ± 0.21
Pancreas 4.65 ± 0.18** 1.45 ± 0.18 3.72 ± 0.98* 0.90 ± 0.26
Stomach 0.42 ± 0.09 0.89 ± 0.65 0.16 ± 0.03 0.14 ± 0.10
Small intestine 0.55 ± 0.02 0.78 ± 0.39 0.20 ± 0.04* 0.10 ± 0.02
Colon 0.79 ± 0.14 0.59 ± 0.10 0.31 ± 0.08* 0.11 ± 0.03
Liver 0.50 ± 0.06 0.64 ± 0.07 0.51 ± 0.05 0.46 ± 0.02
Muscle 0.17 ± 0.03 0.20 ± 0.05 0.02 ± 0.01 0.02 ± 0.00
Bone 0.21 ± 0.03 0.31 ± 0.03 0.23 ± 0.03 0.22 ± 0.03
Tumour 2.06 ± 0.41* 1.47 ± 0.42 1.14 ± 0.10 0.66 ± 0.26
Tumour-to-blood 4.08 ± 0.54 1.89 ± 0.42 62.46 ± 3.58 36.24 ± 13.73
Tumour-to-liver 4.11 ± 0.67 2.28 ± 0.60 2.78 ± 0.21 1.47 ± 0.56
Tumour-to-kidney 0.67 ± 0.14 0.38 ± 0.13 0.62 ± 0.07 0.33 ± 0.16
Tumour-to-muscle 12.26 ± 4.01 7.20 ± 0.90 55.89 ± 32.86 27.27 ± 11.92
Tumour-to-pancreas 0.44 ± 0.08 1.01 ± 0.23 0.28 ± 0.08 0.62 ± 0.22
*P< 0.05.; **P< 0.001. Data in percentage of injected dose per gram of tissue
(%ID/g), expressed as mean ± SD at 1 and 24 h p.i. (n= 3).
Figure 5 Therapeutic effect of 177Lu-DOTA-PEG5k-Lys-BN in
mice with PC-3 tumour xenografts. The graph shows the
comparison of treatment with high specific activity (2 × 20 MBq/
0.3 nmol peptide each; group D) and low specific activity
(2 × 20 MBq/3.0 nmol peptide each; group C). Besides, it shows the
effect of unlabelled DOTA-PEG5k-Lys-BN (2 × 3.0 nmol peptide; group
B) on tumour growth. Data are expressed as the volume of tumour
relative to the volume in the same animal immediately before the
first injection (mean± SD of six animals).
Figure 6 Therapeutic effect of the 177Lu-labelled BN analogues.
Peptides were labelled with high specific activity (2 × 20 MBq/
0.3 nmol peptide each) and injected in mice with PC-3 tumour
xenografts. The graph shows the comparison of treatment with the
PEGylated (group D) and the non-PEGylated (group F) 177Lu-labelled
BN analogues. Besides, it shows the influence of timing the second
dose (second dose at day 7 vs. day 14; group E vs. group D). Data
are expressed as the volume of tumour relative to the volume in the
same animal immediately before the first injection (mean± SD of six
animals).
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213Bi and showed anti-tumour effectiveness in mice with
PC-3 xenografts. Regarding in vitro evaluation and biodis-
tribution data, our 177Lu-DOTA-Lys-BN analogue showed
pharmacokinetic properties which are comparable to
those of the above-mentioned BN analogues, except for
the higher tumour uptake and the better retention profile
of AMBA and DOTA-PESIN. Therefore, we wanted to
improve the radiotherapy relevant characteristics further
by PEGylating 177Lu-DOTA-Lys-BN.
In vitro, time-dependent cell uptake and internalisa-
tion showed slower binding kinetics for the PEGylated
BN analogue. These findings are in line with the results
of PEGylating other biomolecules reported in the litera-
ture [31]. PEG is also reported to affect target associ-
ation and dissociation rates of antibody fragments
negatively [32]. These aspects may apply to our 177Lu-
DOTA-PEG5k-Lys-BN and explain why binding affinity
of this analogue in vitro was slightly reduced (Additional
file 1), the steady state was reached later, and the total
cell binding was lower in comparison with that of the
non-PEGylated counterpart.
Previously, we could confirm that PEGylation improves
the stability of BN toward enzymatic degradation [26]. In
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to a considerable increase in stability in vitro (Figure 2).
The half-life (t1/2) of
177Lu-DOTA-PEG5k-Lys-BN in
human plasma was 5.6-fold higher in comparison with
that of non-PEGylated 177Lu-DOTA-Lys-BN. In com-
parison to 177Lu-AMBA, which is more stable in human
plasma (t1/2 = 38.8 h) [23] than
177Lu-DOTA-PESIN (t1/
2 = 8.4 h) [25], the in vitro half-life of
177Lu-DOTA-Lys-
BN in human plasma (t1/2 =28.8 h) was in the same range
but was markedly higher with the PEGylated BN
analogue (t1/2 = 160.8 h).
The biodistribution data, in which 0.002 nmol of
177Lu-AMBA and 177Lu-DOTA-8-AOC-BN(7–14)
(HPLC purified) was injected per mouse [23], and the
data of 177Lu-DOTA-PESIN (0.2 nmol peptide) [25]
were compared with our biodistribution data, in which
0.075 nmol of the 177Lu-labelled BN analogues were
injected. This 0.075 nmol is the nearest possible approxi-
mation to the 0.002 nmol without HPLC purification,
which is desired in clinics. In comparison with 177Lu-
AMBA, our 177Lu-DOTA-Lys-BN showed an approxi-
mately fourfold lower kidney uptake 1 h p.i., whereas the
kidney uptake of the 177Lu-DOTA-PEG5k-Lys-BN
analogue was 2.3-fold lower at 1 h p.i. Both compounds
showed a faster clearance from the kidneys within 24 h
p.i. Kidney accumulation and washout of our 177Lu-
DOTA-Lys-BN and 177Lu-DOTA-PEG5k-Lys-BN were
comparable to those of 177Lu-DOTA-PESIN (3.8 ± 0.34%
ID/g at 1 h p.i.), even though Gelofusine and polygluta-
mic acid were co-administered with 177Lu-DOTA-PESIN
for the reduction of renal uptake [25]. Furthermore, the
GI uptake was much lower with 177Lu-DOTA-Lys-BN
and 177Lu-DOTA-PEG5k-Lys-BN at 1 and 24 h p.i. com-
pared with that in 177Lu-AMBA (11.2%ID and 5.8% ID,
respectively) and 177Lu-DOTA-8-AOC-BN(7–14) (9.7%
ID and 1.7% ID, respectively) [23]. However, the signifi-
cantly higher blood level at 1 h p.i. after PEGylation
might cause higher bone marrow toxicity and could
therefore be a potential drawback of PEGylation.
177Lu-DOTA-PEG5k-Lys-BN showed significantly
higher tumour uptake at 1 h p.i. in comparison with the
non-PEGylated counterpart. The higher enzymatic sta-
bility as well as the longer blood circulation may have
compensated for the slower binding kinetics and the
lower receptor affinity of DOTA-PEG5k-Lys-BN. In
order to compare the cumulative radioactivity over 24 h
of each conjugate in the tumour, the AUC value of
177Lu-DOTA-Lys-BN was arbitrarily set to 1. The com-
parison showed a relative AUC value of 1.6 (P< 0.0006)
for 177Lu-DOTA-PEG5k-Lys-BN.
The second hypothesis that PEGylation prolongs the
tumour retention was also proven. Even though PEGyla-
tion lowered the tumour washout only slightly between 1
and 24 h p.i., there was more 177Lu-DOTA-PEG5k-Lys-BNretained in the tumour between 0 and 24 h p.i. The
extended tumour retention for the 177Lu-DOTA-PEG5k-
Lys-BN might be explained by the improved enzymatic
stability of the peptide derivative, and the extended reten-
tion might be due to the enhanced permeation and reten-
tion in the tumour. On the basis of the biodistribution
data with 177Lu-AMBA [23] and 177Lu-DOTA-PESIN
[25], both BN analogues showed higher tumour uptakes
(6.35± 2.23% ID/g and 11.6± 1.4%ID/g at 1 h p.i., respect-
ively) and better retention profiles than our 177Lu-labelled
BN analogues. However, compared to 177Lu-DOTA-8-
AOC-BN(7–14) [23] (2.84 ± 1.65% ID/g at 1 h p.i.), our
177Lu-DOTA-Lys-BN analogue showed a similar tumour
uptake, but the uptake of 177Lu-DOTA-PEG5k-Lys-BN
was higher. This comparison, however, must be looked at
with due care because the study designs differ insofar as
different peptide amounts were injected.
The third hypothesis, i.e. that PEGylation improves
tumour-to-non-target ratios, could partially be con-
firmed. The tumour-to-non-target ratios were rather
similar for both derivatives. However, in comparison
with the non-PEGylated BN analogue, the 177Lu-DOTA-
PEG5k-Lys-BN analogue exhibited a higher tumour up-
take and a prolonged tumour retention which resulted
in increased tumour-to-pancreas ratios at all time points
and in higher tumour-to-liver and tumour-to-kidney
ratios at 24 h p.i. (Figure 3).
Alongside PEGylation, the influence of the specific ac-
tivity on biodistribution was evaluated. 177Lu-DOTA-
PEG5k-Lys-BN injected at two different peptide amounts
corresponding to the amount that was injected in the
therapy studies (0.3 or 3.0 nmol, respectively) affected
the uptake into receptor-expressing tissues. The amount
of 0.3 nmol was selected to approximate the 0.22 nmol
of the AMBA therapy study because these amounts of
0.3 nmol have proven to be the limit for high specific
labelling, i.e. the labelling is reproducible without any
loss in yield. The amount of 3.0 nmol however was
selected because a preliminary study (data not presented)
had suggested that peptide amounts in this range
markedly reduce the uptake into non-target receptor
positive tissues. In comparison with a low peptide amount,
applying a high peptide amount resulted in a marked re-
duction in pancreas and colon uptake which would lower
the risk of radiotoxic side effects induced by radionuclide
therapy (Figure 4). However, the cumulative radioactivity
in the tumour was significantly higher with a low peptide
amount. The dosimetry showed that the absorbed dose
into the tumour was 1.7-fold higher with the radiotracer
of high specific activity, which would presumably indicate
a higher anti-tumour effect. Furthermore, a lower accu-
mulation in the kidneys within 24 h p.i. was observed with
177Lu-DOTA-PEG5k-Lys-BN at a low amount of peptide
(Table 3), which would indicate a reduced risk of
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incidence of BN-related toxicity after i.v. injection could
be reduced using a low amount of peptide.
The radionuclide therapy studies (Table 1) showed a
higher anti-tumour effectiveness with 177Lu-DOTA-
PEG5k-Lys-BN (group D) compared with
177Lu-DOTA-
Lys-BN (group F) (63% vs. 53% inhibition 3 weeks after
the first dose, respectively; Figure 6). This is in accord-
ance with the biodistribution data, which showed a
higher tumour uptake and retention after PEGylation
(Table 2). As comparative time point, we chose 3 weeks
after the first dose, in order to evaluate the effectiveness
of the different therapy protocols. This is the latest time
point before several mice had to be euthanised upon ful-
filling the endpoint criteria. Therefore, an interpretation
after 3 weeks is not reliable since the groups represent
only individual mice (Figures 5 and 6).
The therapy studies, in which the specific activity was
varied (group C vs. group D), resulted in a markedly
higher therapeutic efficiency when 177Lu-DOTA-PEG5k-
Lys-BN was applied at high specific activity (63% vs. 36%
inhibition 3 weeks after the first dose). The lower
tumour accumulation of 177Lu-DOTA-PEG5k-Lys-BN of
low specific activity resulted in a proportionally faster
tumour growth. We could demonstrate that the reduced
efficacy is not caused by the tumour growth-promoting
effect of the higher peptide amount since unlabelled
DOTA-PEG5k-Lys-BN (group B) did not induce tumour
growth compared with the control group (Figure 5).
These results are in line with previous observations
reported in the literature [25]. The high specific therapy,
as we have seen, was more efficient than the low spe-
cific, which is in accordance with the biodistribution
studies which demonstrate that the uptake in GRPR-
expressing tissues is highest for the lower peptide dose
and is reduced with the higher peptide dose. This
phenomenon is considered to be the result of partial
saturation of receptors in the target tissues at higher
peptide doses.
Furthermore, it can be assumed that an increase in
specific activity would achieve at least the same thera-
peutic efficiency as low specific activity, but the dosage
injected would be lower.
Preliminary therapy studies (Additional file 1: Figure
S8), as expected, showed that the administration of two
doses (2 × 20 MBq= 40 MBq) was more effective in
tumour growth inhibition than application of a single
dose (20 MBq). As shown with in vitro autoradiography
(Additional file 1: Figure S9), there was no long-lasting
down-regulation of BN2/GRP receptors in the tumour
after treatment, which suggests that it is sensible to
apply a multiple dosage. Therefore, two different two-
dose regimens were evaluated in the current therapy
studies. Applying the second dose at day 14 was chosento match the AMBA therapy study. The preliminary
study showed that the tumour started to grow after
14 days regardless of the second injection. Since the
cause for this might have been that the tumour was
already too large to respond to the treatment, the second
application was introduced at day 7 in order to hit the
tumour in an earlier state. The therapeutic efficiency
was increased even further when the second dose of
177Lu-DOTA-PEG5k-Lys-BN (group E) was applied
7 days after the first dose instead of 14 days (73% vs.
63% inhibition at day 21) (group D).
Comparing our study with the therapy studies with
177Lu-AMBA [23], 177Lu-DOTA-PESIN [25] (2× 28 MBq,
0.2 nmol) and 177Lu-DOTA-8-AOC-BN(7–14) [24], we
found the tumour growth inhibition with our PEGylated
BN analogue to be lower than with AMBA (approximately
73% vs. approximately 82%) but higher than with DOTA-
PESIN (approximately 73% vs. approximately 45%) and
roughly the same as with 177Lu-DOTA-8-AOC-BN(7–14)
(approximately 73% vs. approximately 79%) 3 weeks after
the first dose. However, such a comparison is not fully
conclusive since these therapy studies differ in tumour
size at the beginning of therapy, injected peptide amount,
administered radiation dose and injection interval.
In order to assess the risk for nephrotoxicity related to
radionuclide therapy, a rough dosimetric estimate for an
adult male was performed based on the biodistribution,
in which 0.3 or 3.0 nmol of the 177Lu-DOTA-PEG5k-
Lys-BN analogue were applied. This estimate implies
that an administration of approximately 2 GBq of either
low or high specific 177Lu-DOTA-PEG5k-Lys-BN analogue
would result in absorbed kidney doses of approximately
18.8 or 24.6 Gy, respectively. These doses would not
exceed the acceptable safe limit of 23 to 27 Gy [33]. The
administration of 2 GBq would supposedly be necessary
to reach a tumour dose of 50 Gy (supposed that the
absorbed dose into the pancreas corresponds to the
tumour dose), which is needed for treatment as external
beam radiation therapy and brachytherapy data suggest
[34-36]. A further step in the risk assessment was 99mTc-
DMSA scintigraphy which showed that there was no
kidney damage in the mice treated with high or low
specific 177Lu-DOTA-PEG5k-Lys-BN analogue (group H
and I) since there was no significant difference in renal
99mTc-DMSA uptake of control and treated mice. Besides,
serum analysis confirmed the absence of renal toxicity
(Additional file 1).
Conclusions
PEGylation, increasing the specific activity of the
radiolabelled bombesin analogue and shortening the
injection interval proved to be effective strategies to en-
hance the radiotherapeutic efficacy and to provide a
favourable risk-profile at the same time. Tumour targeting
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the 177Lu-DOTA-PEG5k-Lys-BN analogue of high specific
activity. The estimate of the absorbed doses for an adult
male implied that the absorbed kidney doses would lie
below the threshold of kidney damage. Taking the positive
features into account, which have been observed in this
study, we believe that PEGylation of small molecular
weight radiopharmaceuticals is an efficient strategy to
improve their potential for a successful application in
targeted radionuclide therapy.
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